This month, in Allergan USA, Inc. v. MSN Laboratories Private Ltd., the Federal Circuit added to the ongoing patent-family drama...

The United States Patent and Trademark Office (USPTO) has proposed changes to terminal disclaimer rules that could significantly...

mRNA-Based Vaccine and Other Therapeutics mRNA-based vaccines have become one of the most discussed technologies both inside and outside...

The district court in Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc., Civil Action No. 20-430-RGA (D. Del.) was asked...

The Federal Circuit recently reversed a PTAB obviousness finding because it found no motivation to combine features of the two cited...

While e-signatures have been accepted for transactions in many facets of life for years, the USPTO finally has approved e-signatures for...

Only “natural persons” can be named “inventors” on U.S. patents. But last month, the U.S. Patent and Trademark Office (USPTO) issued...

Last week, the United States Patent and Trademark Office (USPTO) published the Guidelines for Assessing Enablement in Utility...

In alignment with both the U.S. Patent & Trademark Office's determination in 2020 (affirmed by the U.S. Court of Appeals for the Federal...

Because judicial resources are limited, virtually all courts impose length limitations, such as word, page, or line limits, for briefing....

Manufacturers of pharmaceuticals, biologics, and herbicides, as well as companies in virtually every industry, routinely make statements...

The USPTO issued clarifying guidance on whether Graphical User Interfaces (GUIs) can be covered by design patents. The relevant statute...